Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.

Recently published Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, ...

EVEREST MED (01952.HK) announced that, in relation to the exclusive licensing and collaboration agreement signed with Travere ...

The first half of 2026 saw the FDA approve 5 notable first-in-class therapies across obesity, AML, kidney disease, hearing loss, and bladder cancer. The first half of 2026 brought a steady stream of ...

June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies ...

Food - Allergen - Peanut Distribution: British ColumbiaOntarioQuebec See the affected products and product photos for this ...

LaTonya Johnson is the owner and lead electrologist of Minnesota Electrolysis LLC, where she has dedicated years to helping clients regain confidence through permanent hair ...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm ...

With combination therapies and multiple treatment options available for patients, nephrology is in a “therapeutic revolution, ...

Vera Therapeutics faces tough IgAN competition as Trutakna looks late and undifferentiated. A rich valuation adds risk. Read ...